维生素K2与D对主动脉瓣钙化患者的影响:随机双盲临床试验
在主动脉瓣钙化评分>300 AU的社区老年男性中,每日补充720 µg MK-7加25 µg维生素D共24个月,未能减缓主动脉瓣钙化评分的进展。主动脉瓣面积、峰值射流速度、主动脉及冠状动脉钙化进展、心脏瓣膜手术及临床事件与安慰剂组均无显著差异,但dp-ucMGP显著降低。
要点
- 在AVC评分>300 AU的老年男性中,2年MK-7加维生素D补充未影响AVC进展。
- 主动脉瓣面积、峰值射流速度及主动脉/冠状动脉钙化进展均无显著组间差异。
- 心脏瓣膜手术、全因死亡及心血管事件发生率组间无差异,dp-ucMGP显著降低。
核心结论
- 在AVC评分>300 AU的老年男性中,2年MK-7加维生素D补充未影响AVC进展。
研究设计与样本
- 随机、双盲、多中心试验,纳入社区男性AVC评分>300 AU者365例,随机接受每日720 µg MK-7加25 µg维生素D或安慰剂治疗24个月。
- 平均年龄71.0(±4.4)岁。
主要发现
- AVC评分平均增加:干预组275 AU(95%CI 225-326),安慰剂组292 AU(95%CI 246-338),平均差异17 AU(95%CI -86至53,P=0.64)。
- 主动脉瓣面积平均变化0.02 cm2(95%CI -0.09至0.12,P=0.78),峰值射流速度平均变化0.04 m/s(95%CI -0.11至0.02,P=0.21)。
- 主动脉及冠状动脉钙化评分进展组间无显著差异。
- 心脏瓣膜手术(1例 vs 2例,P=0.99)、全因死亡(1例 vs 4例,P=0.37)、心血管事件(10例 vs 10例,P=0.99)均无差异。
- 与安慰剂组相比,MK-7加维生素D组dp-ucMGP显著降低(-212 pmol/L vs 45 pmol/L,P<0.001)。
关键数值与推荐
- 入组标准:社区男性,心脏非增强CT测得AVC评分>300 AU。
- 干预方案:每日720 µg MK-7加25 µg维生素D,持续24个月。
临床怎么用
- 对于AVC评分>300 AU的老年男性,不推荐以减缓AVC进展为目的常规补充MK-7加维生素D。
局限性
- 仅纳入社区老年男性,结果不能外推至女性或其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis. METHODS: In a randomized, double-blind, multicenter trial, men from the community with an AVC score >300 arbitrary units (AU) on cardiac noncontrast computer tomography were randomized to daily treatment with tablet 720 µg MK-7 plus 25 µg vitamin D or matching placebo for 24 months. The primary outcome was the change in AVC score. Selected secondary outcomes included change in aortic valve area and peak aortic jet velocity on echocardiography, heart valve surgery, change in aortic and coronary artery calcification, and change in dp-ucMGP (dephosphorylated-undercarboxylated matrix Gla-protein). Safety outcomes included all-cause death and cardiovascular events. RESULTS: From February 1, 2018, to March 21, 2019, 365 men were randomized. Mean age was 71.0 (±4.4) years. The mean (95% CI) increase in AVC score was 275 AU (95% CI, 225-326 AU) and 292 AU (95% CI, 246-338 AU) in the intervention and placebo groups, respectively. The mean difference on AVC progression was 17 AU (95% CI, -86 to 53 AU; P=0.64). The mean change in aortic valve area was 0.02 cm2 (95% CI, -0.09 to 0.12 cm2; P=0.78) and in peak aortic jet velocity was 0.04 m/s (95% CI, -0.11 to 0.02 m/s; P=0.21). The progression in aortic and coronary artery calcification score was not significantly different between patients treated with MK-7 plus vitamin D and patients receiving placebo. There was no difference in the rate of heart valve surgery (1 versus 2 patients; P=0.99), all-cause death (1 versus 4 patients; P=0.37), or cardiovascular events (10 versus 10 patients; P=0.99). Compared with patients in the placebo arm, a significant reduction in dp-ucMGP was observed with MK-7 plus vitamin D (-212 pmol/L versus 45 pmol/L; P<0.001). CONCLUSIONS: In elderly men with an AVC score >300 AU, 2 years MK-7 plus vitamin D supplementation did not influence AVC progression. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03243890.
引用
- Diederichsen ACP, Lindholt JS, Möller S, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation. 2022. PMID: 35465686. doi:10.1161/CIRCULATIONAHA.121.057008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。